株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

成長ホルモン欠損症 (GHD):主要19ヶ国の市場予測 (2018〜2028年)

Epiomic Epidemiology Series: Growth Hormone Deficiency Forecast in 19 Major Markets 2018-2028

発行 Black Swan Analysis 商品コード 357989
出版日 ページ情報 英文 80 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
成長ホルモン欠損症 (GHD):主要19ヶ国の市場予測 (2018〜2028年) Epiomic Epidemiology Series: Growth Hormone Deficiency Forecast in 19 Major Markets 2018-2028
出版日: 2018年09月01日 ページ情報: 英文 80 Pages
概要

成長ホルモン欠損症 (GHD) は、正常な下垂体および視床下部組織の破壊から生じ、脳下垂体前葉からの成長ホルモン(GH)の分泌不全によって特徴付けられます。 GHDは個人の生活のあらゆる時点で発生する可能性がありますが、主に幼児期発症 (CO) または成人発症 (AO) として定義されています。 AOが後天的または特発性の傾向があるのに対して、COの大部分は先天的です。

当レポートでは、世界の主要19ヶ国における成長ホルモン欠損症 (GHD) の治療薬の市場について分析し、各国のGHDの有病者数の推移や将来予測 (今後10年間分)、男女別・年齢層別 (5歳刻み) の詳細動向、主な併発症の罹患状況、主なリスク要因、予後の違い (地域別・民族別など)、現在・将来の主要な治療法、診断・治療の実施状況などについて調査しております。

図表

  • イントロダクション
  • 疾患の原因
  • リスク要因と予防法
  • 疾患の診断
  • 地域別・民族別の差異
  • 疾患の予後と臨床経過
  • 疾患に関連する主な併存症/特徴
  • 患者数の定量化方法
  • 成長ホルモン欠損症 (GHD) の有病者数の最大推定値 (トップライン)
    • GHD患者の特徴
      • 病因
      • その他の特徴
    • GHD患者の共存症
      • ホルモン障害
      • 骨構造異常
      • その他の共存症
  • 本文中の略語
  • その他のサービス・ソリューションについて
    • レポート・刊行物
    • オンライン疫学データベース
    • オンライン薬価データベース
  • 参考文献
  • 付録

分析対象国

  • 米国、カナダ、フランス、ドイツ、イタリア、スペイン、英国、ポーランド、オランダ、ロシア、トルコ、日本、中国、韓国、インド、オーストラリア、ブラジル、メキシコ、アルゼンチン
目次
Product Code: GHDI0020918

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Growth Hormone Deficiency in 19 Major Markets

Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH) from the anterior pituitary gland. GHD can occur at any point during an individual's life but is primarily defined as being of childhood onset (CO) or adult onset (AO). Age at onset tends to denote a different underlying pathology for the deficiency. The majority of CO is congenital, whereas AO forms tend to be acquired or idiopathic. For congenital forms, there are three types linked with different genetic inheritance patterns. Acquired types tend to arise from a variety of tumours of the hypothalamus/pituitary as well as brain trauma, surgery/treatment of extra-cranial tumours, etc.

This report provides the current prevalent population for GHD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, GHD patients grouped by various features and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GHD include:

  • Diabetes mellitus and other issues with glucose regulation (including IGT and metabolic syndrome)
  • Hypertension
  • Obesity
  • Osteopaenia, osteoporosis and increased frequency of fractures
  • Liver disease
  • Cerebrovascular diseases
  • Cardiovascular diseases

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Ability to quantify patient populations in global GHD market to target the development of future products, pricing strategies and launch plans.

Further insight into the prevalence of the subdivided types of GHD and identification of patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Better understanding on the impact of specific co-morbid conditions on the prevalent population of GHD patients.

Identification of GHD patient sub-populations that require treatment.

Better understanding of the specific markets that have the largest number of GHD patients.

Table of Contents

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR GROWTH HORMONE DEFICIENCY
  • FEATURES OF GROWTH HORMONE DEFICIENCY PATIENTS
  • AETIOLOGY
  • OTHER FEATURES
  • COMORBIDITIES OF GROWTH HORMONE DEFICIENCY PATIENTS
  • HORMONAL DISTURBANCES
  • BONE STRUCTURE ABNORMALITIES
  • OTHER COMORBIDITIES
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Prevalence of GHD, total (000s)
  • Table 2. Prevalence of GHD, males (000s)
  • Table 3. Prevalence of GHD, females (000s)
  • Table 4. GHD patients by aetiology, total (000s)
  • Table 5. Acquired GHD patients by aetiology, total (000s)
  • Table 6. GHD patients with pituitary/hypothalamus tumours by pituitary adenoma functional status, total (000s)
  • Table 7. GHD patients with pituitary/hypothalamus tumours by pituitary adenoma size, total (000s)
  • Table 8. GHD patients by onset type, total (000s)
  • Table 9. GHD patients by BMI, total (000s)
  • Table 10. GHD patients by pituitary hormonal deficiencies, total (000s)
  • Table 11. GHD patients with TSH deficiency, total (000s)
  • Table 12. GHD patients with ACTH deficiency, total (000s)
  • Table 13. GHD patients with LH/FSH deficiency, total (000s)
  • Table 14. GHD patients with ADH deficiency, total (000s)
  • Table 15. GHD patients by bone density status, total (000s)
  • Table 16. GHD patients with bone fractures, total (000s)
  • Table 17. GHD patients with bone fractures by site, total (000s)
  • Table 18. GHD patients with diabetes mellitus, total (000s)
  • Table 19. GHD patients with dyslipidaemia, total (000s)
  • Table 20. GHD patients with hypertension, total (000s)
  • Table 21. GHD patients with metabolic syndrome, total (000s)
  • Table 22. GHD patients with visual field loss, total (000s)
  • Table 23. GHD patients with cerebrovascular disease, total (000s)
  • Table 24. GHD patients with arthritis, total (000s)
  • Table 25. Abbreviations and acronyms used in the report
  • Table 26. USA prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 27. USA prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 28. Canada prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 29. Canada prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 30. France prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 31. France prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 32. Germany prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 33. Germany prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 34. Italy prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 35. Italy prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 36. Spain prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 37. Spain prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 38. UK prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 39. UK prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 40. Poland prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 41. Poland prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 42. Netherlands prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 43. Netherlands prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 44. Russia prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 45. Russia prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 46. Turkey prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 47. Turkey prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 48. Japan prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 49. Japan prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 50. China prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 51. China prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 52. South Korea prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 53. South Korea prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 54. India prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 55. India prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 56. Australia prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 57. Australia prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 58. Brazil prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 59. Brazil prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 60. Mexico prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 61. Mexico prevalence of GHD by 5-yr age cohort, females (000s)
  • Table 62. Argentina prevalence of GHD by 5-yr age cohort, males (000s)
  • Table 63. Argentina prevalence of GHD by 5-yr age cohort, females (000s)
Back to Top